Therapeutic: gastrointestinal anti-inflammatories—therapeutic
Treatment of mild-to-moderately active ulcerative colitis.
Drug is metabolized in the colon to mesalamine (5-aminosalicylic acid), which is a local anti-inflammatory. Therapeutic Effects: Reduction in the symptoms of ulcerative colitis.
Adverse Reactions/Side Effects
GI: HEPATOTOXICITY, abdominal pain, diarrhea.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
Be alert for signs of hepatotoxicity, including anorexia, abdominal pain, severe nausea and vomiting, yellow skin or eyes, fever, sore throat, malaise, weakness, facial edema, lethargy, and unusual bleeding or bruising. Notify physician of these signs immediately.
Absorption: Absorption is low and variable; drug is delivered intact to the colon.
Distribution: Mostly delivered intact to the colon; remainder of distribution unknown.
Metabolism and Excretion: Following delivery to the colon, bacteria break balsalazide down into mesalamine (5-aminosalicylic acid) and an inactive metabolite; mostly excreted in feces.
Half-life: Mesalamine—12 hr (range 2–15 hr).
TIME/ACTION PROFILE (decreased symptoms)
|ROUTE ||ONSET ||PEAK ||DURATION |
|PO ||unknown ||up to 8 wk ||unknown |
Contraindicated in: Hypersensitivity to salicylates or other metabolites.
Use Cautiously in: Pyloric stenosis (may have prolonged gastric retention of capsules); OB: Use only if clearly needed; Lactation/Pedi: Safety not established.
PO (Adults): 3 750-mg capsules 3 times daily for 8–12 wk.
PO (Children 5–17 yr): 3 750-mg capsules 3 times daily for up to 8 wk or 1 750-mg capsule 3 times daily for up to 8 wk.